CA
NZ
UK
AU
IND
US
Qualcomm (NASDAQ: QCOM) disclosed that selling shareholders will collectively resell 17,826,566 shares of its common stock, each with a par value of $0.0001. The prospectus supplement was filed on July 31, 2026, marking a notable secondary distribution for the chipmaker and expanding the publicly …
IBM anticipates that its investments in quantum computing will begin having a measurable impact on its earnings between 2028 and 2029. The company's CEO, Arvind Krishna, indicated that the push into quantum technology is aligned with projections suggesting a trillion-dollar market value by the …
South Korea's chip giants, SK Hynix and Samsung Electronics, experienced their largest stock rally ever, soaring over 20% on Friday following a record gain in the Kospi index. The Kospi achieved its best-ever daily performance, a stark contrast to the tumultuous recent history marked …
Reddit is managing a challenging environment as CEO Steve Huffman revealed that Google’s AI Overviews are unable to replace the traditional search results, often referred to as the "10 blue links," which previously drove substantial referral traffic to the site. Huffman highlighted the decline …
Strategic Initiatives Highlighted in Q2 Earnings Call
Alnylam (Nasdaq:ALNY) reported second-quarter 2026 results on 30 July, filed with the SEC as Exhibit 99.1 to an 8-K that day. The stock closed the session at $205.48, down 28.31% from the prior close of $286.62, onVolumeof 9.75 million shares, roughly seven times the …
Amgen (Nasdaq:AMGN) ended at $385.16, a little under 2% below the record close of $393.10 it set on 28 July, according to aggregated market data data. That 28 July session was the year's most violent: shares leapt roughly 4.5%, though vendors put the figure …
Pharmaceuticals (Nasdaq:ARWR). Arrowhead's transformation from a licensing shop into a commercial company has a date on it: when the FDA approved REDEMPLO (plozasiran) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome. It is dosed as a subcutaneous injection …
Ascendis Pharma (Nasdaq:ASND) closed at $243.91 at last closing, down $7.16, or 2.85%, on the day. That single session sits inside a longer fade: the American depositary shares have given back roughly 12% since closing at $277.18 on 8 July, and now trade nearer …
Axsome Therapeutics (Nasdaq:AXSM) closed at $217.99 at last closing, down $16.65 or 7.10% on the session, according to aggregated market data. The drop more than erased the prior day's 3.17% gain and capped a week in which the stock fell from $241.00 on 24 …
Please wait processing your request...